WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998003502) SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/003502    International Application No.:    PCT/US1997/013375
Publication Date: 29.01.1998 International Filing Date: 24.07.1997
Chapter 2 Demand Filed:    17.12.1997    
IPC:
C07D 401/04 (2006.01)
Applicants: CELGENE CORPORATION [US/US]; 7 Powder Horn Drive, Warren, NJ 07059 (US) (For All Designated States Except US).
MULLER, George, W. [US/US]; (US) (For US Only).
STIRLING, David, I. [GB/US]; (US) (For US Only).
CHEN, Roger, Shen-Chu [US/US]; (US) (For US Only)
Inventors: MULLER, George, W.; (US).
STIRLING, David, I.; (US).
CHEN, Roger, Shen-Chu; (US)
Agent: COLLINS, Bruce, M.; Mathews, Collins, Shepherd & Gould, P.A., Suite 306, 100 Thanet Circle, Princeton, NJ 08540-3674 (US)
Priority Data:
08/690,258 24.07.1996 US
08/701,494 22.08.1996 US
60/048,278 30.05.1997 US
Title (EN) SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS
(FR) 2-(2,6- DIOXOPIPERIDINE-3-YL)-PHTALIMIDES ET -1-OXO-ISO-INDOLINES SUBSTITUES ET METHODES POUR REDUIRE LES TAUX DE TNF-alpha
Abstract: front page image
(EN)Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNF$g(a) in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline and 1,3-dioxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.
(FR)Les 2-(2,6- dioxopipéridine-3-yl)-phtalimides substitués et les 1-oxo-2-(2,6- dioxopipéridine-3-yl)-iso-indolines substituées réduisent les taux de TNF-alpha chez le mammifère. Les formes utilisées sont en particulier 1-oxo-2-(2,6-dioxo-3-méthylpipéridine-3-yl)-4,5,6,7-tétrafluoro-iso-indoline et 1,3-dioxo-2-(2,6-dioxo-3-méthylpipéridine-3-yl)-4-amino-iso-indoline.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU.
African Regional Intellectual Property Organization (GH, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)